Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma
Xiaowei Mao,1,2,* Jiabing Liu,3,* Fang Hu,1,* Yanjie Niu,1 Feng Pan,1 Xiaolong Fu,3 Liyan Jiang1 1Pulmonary and Critical Care Medicine, Shanghai Jiao Tong University, Shanghai Chest Hospital, Shanghai, People’s Republic of China; 2Department of Pulmonary and Critical Care Med...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-03-01
|
| Series: | Cancer Management and Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/serum-nse-is-early-marker-of-transformed-neuroendocrine-tumor-after-eg-peer-reviewed-fulltext-article-CMAR |
| _version_ | 1811328796393996288 |
|---|---|
| author | Mao X Liu J Hu F Niu Y Pan F Fu X Jiang L |
| author_facet | Mao X Liu J Hu F Niu Y Pan F Fu X Jiang L |
| author_sort | Mao X |
| collection | DOAJ |
| description | Xiaowei Mao,1,2,* Jiabing Liu,3,* Fang Hu,1,* Yanjie Niu,1 Feng Pan,1 Xiaolong Fu,3 Liyan Jiang1 1Pulmonary and Critical Care Medicine, Shanghai Jiao Tong University, Shanghai Chest Hospital, Shanghai, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Radiation Oncology, Shanghai Jiao Tong University, Shanghai Chest Hospital, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Liyan Jiang; Xiaolong Fu, Email jiang_liyan2000@126.com; xlfu1964@126.comBackground: Transformation to a lung neuroendocrine tumor (LNET) is a mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Serum neuron-specific enolase (NSE) is a useful marker in the detection of LNET. Therefore, we explored the clinical significance of serum NSE levels in the detection of transformed neuroendocrine tumors after EGFR-TKI therapy.Methods: We report a cohort of 5 cases in our treatment group. The characteristics of the patients, pathological diagnoses, immunohistochemistry with molecular detection, laboratory examination, and treatment histories are analyzed. The tumor markers of serum NSE were analyzed. Additionally, we reviewed the publications reporting the tumor markers before and after LNET transformation during EGFR-TKI therapy.Results: Most patients are female (3/5), aged < 60 years old (4/5), nonsmokers (4/5) and harbor the EGFR 19 exon deletion (4/5). The median time of LNET transformation was 19 months (range: 12– 31 months). The clinical characteristics were similar to those reported in previous studies. Laboratory examination revealed an increased NSE level before the LNET is defined. Sixteen publications were reviewed. Of those, 86.67% (13/15) publications showed an increased level of NSE when the LNET transformation was defined.Conclusion: Adenocarcinoma tumors in non-smokers, young patients harboring the EGFR 19 exon deletion tended to transform to LNETs after EGFR-TKI therapy. Combining our findings and a review of the literature, we suggest that serum NSE may be a useful tumor marker to predict neuroendocrine tumor transformation.Keywords: transformation, EGFR-TKI, target therapy, lung neuroendocrine tumor, neuron-specific enolase |
| first_indexed | 2024-04-13T15:31:20Z |
| format | Article |
| id | doaj.art-bbd56d4455fb433eaa60fe81a689ab35 |
| institution | Directory Open Access Journal |
| issn | 1179-1322 |
| language | English |
| last_indexed | 2024-04-13T15:31:20Z |
| publishDate | 2022-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Cancer Management and Research |
| spelling | doaj.art-bbd56d4455fb433eaa60fe81a689ab352022-12-22T02:41:22ZengDove Medical PressCancer Management and Research1179-13222022-03-01Volume 141293130274071Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung AdenocarcinomaMao XLiu JHu FNiu YPan FFu XJiang LXiaowei Mao,1,2,* Jiabing Liu,3,* Fang Hu,1,* Yanjie Niu,1 Feng Pan,1 Xiaolong Fu,3 Liyan Jiang1 1Pulmonary and Critical Care Medicine, Shanghai Jiao Tong University, Shanghai Chest Hospital, Shanghai, People’s Republic of China; 2Department of Pulmonary and Critical Care Medicine, Regional Medical Center for National Institute of Respiratory Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, People’s Republic of China; 3Department of Radiation Oncology, Shanghai Jiao Tong University, Shanghai Chest Hospital, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Liyan Jiang; Xiaolong Fu, Email jiang_liyan2000@126.com; xlfu1964@126.comBackground: Transformation to a lung neuroendocrine tumor (LNET) is a mechanism of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI). Serum neuron-specific enolase (NSE) is a useful marker in the detection of LNET. Therefore, we explored the clinical significance of serum NSE levels in the detection of transformed neuroendocrine tumors after EGFR-TKI therapy.Methods: We report a cohort of 5 cases in our treatment group. The characteristics of the patients, pathological diagnoses, immunohistochemistry with molecular detection, laboratory examination, and treatment histories are analyzed. The tumor markers of serum NSE were analyzed. Additionally, we reviewed the publications reporting the tumor markers before and after LNET transformation during EGFR-TKI therapy.Results: Most patients are female (3/5), aged < 60 years old (4/5), nonsmokers (4/5) and harbor the EGFR 19 exon deletion (4/5). The median time of LNET transformation was 19 months (range: 12– 31 months). The clinical characteristics were similar to those reported in previous studies. Laboratory examination revealed an increased NSE level before the LNET is defined. Sixteen publications were reviewed. Of those, 86.67% (13/15) publications showed an increased level of NSE when the LNET transformation was defined.Conclusion: Adenocarcinoma tumors in non-smokers, young patients harboring the EGFR 19 exon deletion tended to transform to LNETs after EGFR-TKI therapy. Combining our findings and a review of the literature, we suggest that serum NSE may be a useful tumor marker to predict neuroendocrine tumor transformation.Keywords: transformation, EGFR-TKI, target therapy, lung neuroendocrine tumor, neuron-specific enolasehttps://www.dovepress.com/serum-nse-is-early-marker-of-transformed-neuroendocrine-tumor-after-eg-peer-reviewed-fulltext-article-CMARtransformationegfr-tkitarget therapylung neuroendocrine tumorneuron-specific enolase |
| spellingShingle | Mao X Liu J Hu F Niu Y Pan F Fu X Jiang L Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma Cancer Management and Research transformation egfr-tki target therapy lung neuroendocrine tumor neuron-specific enolase |
| title | Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma |
| title_full | Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma |
| title_fullStr | Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma |
| title_full_unstemmed | Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma |
| title_short | Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma |
| title_sort | serum nse is early marker of transformed neuroendocrine tumor after egfr tki treatment of lung adenocarcinoma |
| topic | transformation egfr-tki target therapy lung neuroendocrine tumor neuron-specific enolase |
| url | https://www.dovepress.com/serum-nse-is-early-marker-of-transformed-neuroendocrine-tumor-after-eg-peer-reviewed-fulltext-article-CMAR |
| work_keys_str_mv | AT maox serumnseisearlymarkeroftransformedneuroendocrinetumorafteregfrtkitreatmentoflungadenocarcinoma AT liuj serumnseisearlymarkeroftransformedneuroendocrinetumorafteregfrtkitreatmentoflungadenocarcinoma AT huf serumnseisearlymarkeroftransformedneuroendocrinetumorafteregfrtkitreatmentoflungadenocarcinoma AT niuy serumnseisearlymarkeroftransformedneuroendocrinetumorafteregfrtkitreatmentoflungadenocarcinoma AT panf serumnseisearlymarkeroftransformedneuroendocrinetumorafteregfrtkitreatmentoflungadenocarcinoma AT fux serumnseisearlymarkeroftransformedneuroendocrinetumorafteregfrtkitreatmentoflungadenocarcinoma AT jiangl serumnseisearlymarkeroftransformedneuroendocrinetumorafteregfrtkitreatmentoflungadenocarcinoma |